Predicting side-effects in venom immunotherapy by basophil activation?
Eberlein-König
B
B
Schmidt-Leidescher
C
C
Behrendt
H
H
Ring
J
J
D000485:Allergens / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D000707:Anaphylaxis / Q000276:immunology / Q000517:prevention & control*; D015703:Antigens, CD / Q000276:immunology; D001491:Basophils / Q000276:immunology*; D001514:Bee Venoms / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D010980:Platelet Membrane Glycoproteins / Q000276:immunology; D060149:Tetraspanin 30; D014862:Wasp Venoms / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use
D000485:Allergens; D015703:Antigens, CD; D001514:Bee Venoms; C554586:CD63 protein, human; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D014862:Wasp Venoms